Search hospitals > Michigan > Chelsea
Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital
Claim this profileChelsea, Michigan 48118
Global Leader in Cancer
Global Leader in Lung Cancer
Conducts research for Breast Cancer
Conducts research for Non-Small Cell Lung Cancer
Conducts research for Adenocarcinoma
205 reported clinical trials
7 medical researchers
Summary
Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital is a medical facility located in Chelsea, Michigan. This center is recognized for care of Cancer, Lung Cancer, Breast Cancer, Non-Small Cell Lung Cancer, Adenocarcinoma and other specialties. Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital is involved with conducting 205 clinical trials across 355 conditions. There are 7 research doctors associated with this hospital, such as Tareq Al Baghdadi, Christopher M. Reynolds, MD, Philip J. Stella, and Elie G. Dib.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
Stage II
2Lung Cancer
Global LeaderStage IV
Stage III
Stage II
Top PIs
Tareq Al BaghdadiSaint Joseph Mercy Hospital7 years of reported clinical research
Expert in Cancer
Expert in Tumors
69 reported clinical trials
127 drugs studied
Christopher M. Reynolds, MDSaint Joseph Mercy Hospital4 years of reported clinical research
Expert in Cancer
Studies Lung Cancer
45 reported clinical trials
99 drugs studied
Philip J. StellaSaint Joseph Mercy Hospital4 years of reported clinical research
Expert in Lung Cancer
Expert in Non-Small Cell Lung Cancer
38 reported clinical trials
89 drugs studied
Elie G. DibSaint Joseph Mercy Hospital4 years of reported clinical research
Expert in Cancer
Studies Multiple Myeloma
34 reported clinical trials
94 drugs studied
Clinical Trials running at Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital
Breast Cancer
Lung Cancer
Cancer
Non-Small Cell Lung Cancer
Gastric Cancer
Gastroesophageal Junction Adenocarcinoma
Esophageal Cancer
Esophageal Adenocarcinoma
Bladder Cancer
Multiple Myeloma
Shorter Chemo-Immunotherapy Without Anthracyclines
for Breast Cancer
This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medications called anti-microtubule agents. It stops cancer cells from growing and dividing and may kill them. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of cancer cells. Cyclophosphamide is in a class of medications called alkylating agents. It works by damaging the cell's deoxyribonucleic acid (DNA) and may kill cancer cells. It may also lower the body's immune response. Docetaxel is in a class of medications called taxanes. It stops cancer cells from growing and dividing and may kill them. Doxorubicin is an anthracycline chemotherapy drug that damages DNA and may kill cancer cells. Pembrolizumab may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Shorter treatment without anthracycline chemotherapy may work the same as the usual anthracycline chemotherapy treatment for early-stage triple negative breast cancer.
Recruiting2 awards Phase 347 criteria
Chemotherapy + Hormone Therapy
for Breast Cancer
This Phase III Trial will determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among premenopausal, early- stage breast cancer (EBC) patients with estrogen receptor (ER)-positive, HER2-negative tumors and 21-gene recurrence score (RS) between 16-25 (for pN0 patients) and 0-25 (for pN1 patients).
Recruiting2 awards Phase 319 criteria
Carvedilol
for Preventing Heart Problems in HER2 Positive Breast Cancer
This study is evaluating whether a drug used to treat high blood pressure and heart failure may help prevent heart damage in patients with breast cancer.
Recruiting2 awards Phase 323 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital?
Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital is a medical facility located in Chelsea, Michigan. This center is recognized for care of Cancer, Lung Cancer, Breast Cancer, Non-Small Cell Lung Cancer, Adenocarcinoma and other specialties. Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital is involved with conducting 205 clinical trials across 355 conditions. There are 7 research doctors associated with this hospital, such as Tareq Al Baghdadi, Christopher M. Reynolds, MD, Philip J. Stella, and Elie G. Dib.